Jefferies analyst Eun K. Yang reiterated a Buy rating and lifted the price target on Radius Health (NASDAQ: RDUS) to $56.00 (from $45.00) following in-line Q4 results but potentially early efficacy data for RAD1901 at ASCO.

Yang commented, "With positive, clean Ph3 data for abaloparatide-SC in PMO, regulatory risks are low, providing a solid valuation floor (~$42/sh by our est.). Although initial efficacy data for RAD1901 is not available yet (at ASCO 2015), if proven to be comparable to IM-injected fulvestrant (only SERD on market; $720M in '14 sales), medical oncologists indicate its potential use in earlier tx settings in ER+ mBC, offering a larger market opportunity (vs. fulvestrant)."

The firm lifted FY 2015 EPS from ($1.91) to ($1.82) and FY 2016 EPS was lowered from $0.18 to ($0.40).

For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.

Shares of Radius Health closed at $47.79 yesterday.